SOPHiA GENETICS Launches Public Offering of Ordinary Shares to Expand Precision Medicine Solutions

SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

On June 16, 2026, SOPHiA GENETICS (Nasdaq: SOPH), a trailblazer in AI-driven precision medicine, made headlines with its announcement regarding the commencement of a proposed underwritten public offering of its ordinary shares. This strategic move is geared towards enhancing the company's capacity to provide data-driven healthcare solutions globally.

The company is poised to grant underwriters an option to purchase an additional 15% of the ordinary shares at the offering price, which excludes the underwriting discount. It's important to note that all the shares in this offering will be sold directly by SOPHiA GENETICS. However, the success and final terms of the offering remain contingent on market conditions and other factors, making it impossible to guarantee completion at a specific time.

Leading the underwriting process is TD Cowen, who has assumed the role of lead book-running manager. To facilitate this offering, SOPHiA GENETICS has filed a registration statement on Form F-3 (File No. 333-289266) with the United States Securities and Exchange Commission (SEC). This statement was officially declared effective on August 15, 2025. Interested parties will find that the offering can only be conducted via a prospectus supplement related to it, which will also be accessible on the SEC's official website.

Moreover, upon availability, copies of the preliminary prospectus and accompanying documentation can be requested from TD Securities (USA) LLC, located at Broadridge Financial Solutions, Edgewood, New York.

In line with regulatory requirements, it's essential to clarify that this announcement does not constitute an offer to sell, nor a solicitation of offers to buy these securities. Similarly, no transactions will occur in jurisdictions where such offers or sales would breach local laws unless duly registered or qualified.

The significance of this offering lies not only in the financial implications but also in its potential to fuel growth in the precision medicine arena, an area where SOPHiA GENETICS stands as a frontrunner. The company’s flagship product, SOPHiA DDM™, exemplifies its commitment to transforming patient care through enhancing access to real-time, data-driven insights across a broad network of health institutions, laboratories, and biopharmaceutical companies worldwide.

SOPHiA GENETICS has positioned itself at the intersection of healthcare and technology, paving the way to a future where personalized medicine is accessible to all. This offering might be a critical step towards achieving those ambitious goals, as it can facilitate further innovations and expand the company's reach in the medical community.

As this situation develops, industry watchers and investors are urged to keep an eye on the company’s filings with the SEC, which will provide further details regarding the offering's structure and timeline. SQL statements indicate that the management team will rigorously assess market conditions to determine the optimal timing for this significant public offering.

In conclusion, SOPHiA GENETICS is on a path to not only bolster its financial standing but also to enhance its leadership in AI-driven precision medicine. With an offering rooted in strategic planning and innovation, the company continues to strive towards revolutionizing healthcare.